Bond.az – InMed Pharmaceuticals (NASDAQ:INM) shares surged 115% Tuesday after announcing a merger deal with Mentari Therapeutics.
The all-stock transaction combines Mentari's migraine pipeline with InMed's public market infrastructure.
Post-close, the combined entity will operate as Mentari Therapeutics.












